OwenAO'ConnorMD

Oncology • New York, NY

Cutaneous Lymphoma, Hematologic Oncology

The Center for Lymphoid Malignancies at Columbia University Medical Center

Join to view full profile

Dr. O'Connor is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. O'Connor's full profile

Already have an account?

Office
1275 York Ave
New York, NY 10065
Phone+1 646-227-3813

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1996 - 2000
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1994 - 1997
Rutgers Robert Wood Johnson Medical SchoolClass of 1994

Certifications & Licensure

NY State Medical License 1996 - 2026
VA State Medical License 2021 - 2024

Awards, Honors, & Recognition

New York Magazine: Top Doctors Castle Connolly, 2014
America's Top Doctors Castle Connolly, 2012-2014
Top Doctors: New York Metro Area Castle Connolly, 2012-2014
America's Top Doctors for Cancer Castle Connolly, 2011-2013
Join now to see all

Clinical Trials

10-Propargyl-10-Deazaaminopterin in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma Start of enrollment: 2002 Aug 01
Completed
Phase 1, Phase 2
Ixabepilone in Treating Patients With Relapsed or Refractory Lymphoproliferative Disorders Start of enrollment: 2002 Oct 01
Completed
Phase 2
Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies Start of enrollment: 2008 Jun 01
Completed
Phase 1
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma Start of enrollment: 2008 Dec 15
Completed
Phase 2
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) Start of enrollment: 2012 Jul 01
Completed
Phase 1, Phase 2
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Start of enrollment: 2013 Jan 31
Completed
Phase 3
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies
TERMINATED
PHASE1, PHASE2
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) Start of enrollment: 2016 Mar 01
Completed
Phase 1
Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma Start of enrollment: 2016 May 25
Terminated
Phase 2, Phase 3
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma Start of enrollment: 2018 May 30
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

16 citations
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
Matthew S. Davids, Owen A. O'Connor, Wojciech Jurczak, Felipe Samaniego, Timothy S. Fenske
Blood Advances. 2021-09-21
2 citations
Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance.
Kana Oiwa, Naoko Hosono, Rie Nishi, Luigi Scotto, Owen A. O'Connor
BMC Cancer. 2021-07-31
7 citations
Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways.
Luigi Scotto, Cristina Kinahan, Eugene Douglass, Changchun Deng, Maryam Safari
Molecular Cancer Therapeutics. 2021-06-09

Abstracts/Posters

Targeting eIF4A Using MZ-735 Potently Induces Cell Death in Lymphoma Cells and Rapidly Represses mRNA Translation at the Global Level and in C-MYC and Other Oncogenes
Owen O'Connor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
An Exploratory Analysis of Brentuximab Vedotin Plus CHP (A+CHP) in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas (ECHELON-2): Impact of Co...
Owen O'Connor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Belinostat Induces High Overall Response Rate (ORR) in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL)
Owen A. O'Connor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder-Diffuse Large B-Cell Lymphoma Subtype
Owen A. O'Connor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Casein Kinase 1 Delta Is a Novel Regulator of mRNA Translation and Druggable Target in Aggressive Lymphomas
Owen O'Connor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Novel Drugs and Clinical Trial-Based Treatments Prolong Survival of Peripheral T-Cell Lymphomas (PTCL) Patients: Single Institution Retrospective Analysis
Owen A. O'Connor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Strategy for Overcoming Crebbp and EP300 Mutations in Lymphoma: Development of First-in-Class HAT Activators
Owen A. O'Connor, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Effect of epigenetic modifier-based combinations on efficacy in patients with peripheral T-cell lymphoma (PTCL): Deciphering impact of mutations in epigenetic operatio...
2019 ASCO Annual Meeting - 6/1/2019
Development of First-in-Class Histone Acetyltransferase (HAT) Activators for Precision Targeting of Epigenetic Derangements in Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Exploring the Present and Future of BTK Inhibition in B-Cell Malignancies: Expert Insights on Practical Implications for Patient Management
60th American Society of Hematology Annual Meeting - 11/30/2018

Press Mentions

Owen a. O'Connor, M.D., Ph.D., Is Recognized by Continental Who's WhoSeptember 21st, 2022
Acalabrutinib MCL Approval Raises Sequencing QuestionsNovember 15th, 2017
FDA Panel: Tolerating Approval Outliers Would Set 'Dangerous Precedent'November 18th, 2023